Grafted Neural Precursors Integrate Into Mouse Striatum, Differentiate and Promote Recovery of Function Through Release of Erythropoietin in MPTP-Treated Mice

ASN Neuro

Volumn 8, Issue 5, 2016, Pages

  Carelli, Stephana ^a   Giallongo, Toniella ^a   Viaggi, Cristina ^b   Gombalova, Zuzana ^a   Latorre, Elisa ^a   Mazza, Massimiliano ^c   Vaglini, Francesca ^b   Di Giulio, Anna Maria ^a   Gorio, Alfredo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

adult neural stem cells; cell therapy; erythropoietin; MPTP; Parkinson s disease; regenerative medicine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; ERYTHROPOIETIN; HOMOVANILLIC ACID; 4 AMINOBUTYRIC ACID; ANTIGEN; CHOLINE ACETYLTRANSFERASE; CHONDROITIN SULFATE PROTEOGLYCAN 4; NERVE PROTEIN; PROTEOGLYCAN; TUMOR ANTIGEN; TYROSINE 3 MONOOXYGENASE; UBC ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL OBSERVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CELL THERAPY; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; GABAERGIC SYSTEM; GENE EXPRESSION; HORIZONTAL GRID TEST; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; MALE; MOTOR DYSFUNCTION ASSESSMENT; MOUSE; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; OBSERVATIONAL STUDY; PARKINSON DISEASE; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; VERTICAL GRID TEST; ANIMAL; BIOLOGICAL THERAPY; C57BL MOUSE; CONVALESCENCE; DISEASE MODEL; GENETICS; METABOLISM; MOVEMENT DISORDERS; MPTP POISONING; MUSCLE STRENGTH; NEURAL STEM CELL; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SURGERY; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; CELL- AND TISSUE-BASED THERAPY; CHOLINE O-ACETYLTRANSFERASE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOVEMENT DISORDERS; MPTP POISONING; MUSCLE STRENGTH; NERVE TISSUE PROTEINS; NEURAL STEM CELLS; PROTEOGLYCANS; RECOVERY OF FUNCTION; TYROSINE 3-MONOOXYGENASE;

EID: 85009255570     PISSN: None     EISSN: 17590914     Source Type: Journal    
DOI: 10.1177/1759091416676147     Document Type: Article

References (60)

1. Agnello D., Bigini P., Villaa P., Mennini T., Cerami A., Brines M. L., Ghezzi P., (2002) EPO exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Research 952(1): 128–134.
2. Barker R. A., (2014) Developing stem cell therapies for Parkinson’s disease: Waiting until the time is right. Cell Stem Cell 15: 539–542.
3. Barker R. A., Barrett J., Mason S. L., Björklund A., (2013) Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. The Lancet Neurology 12: 84–91.
4. Barker R. A., de Beaufort I., (2013) Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. Progress in Neurobiology 110: 63–73.
5. Barzilay R., Ben-Zur T., Bulvik S., Melamed E., Offen D., (2009) Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells and Development 18: 591–601.
6. Bjorklund L. M., Sánchez-Pernaute R., Chung S., Andersson T., Chen I. Y., McNaught K. S., Isacson O., (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proceedings of the National Academy of Sciences 99: 2344–2349.
7. Block M. L., Hong J. S., (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochemical Society Transactions 35: 1127–1132.
8. Brines M., Cerami A., (2008) EPO-mediated tissue protection: Reducing collateral damage from the primary injury response. Journal of Internal Medicine 264: 405–432.
9. Cai J., Donaldson A., Yang M., German M. S., Enikolopov G., & Iacovitti L., (2009) The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson’s disease model. Stem Cells 27: 220–229.
10. Carelli S., Ghilardi G., Bianciardi P., Latorre E., Rubino F., Bissi M., Gorio A., (2016) Enhanced brain release of EPO, cytokines and NO during carotid clamping. Neurological Sciences 37(2): 243–252.
11. Carelli S., Giallongo T., Latorre E., Caremoli F., Gerace C., Basso M. D., Goria A., (2014) Adult mouse post mortem neural precursors survive, differentiate, counteract cytokine production and promote functional recovery after transplantation in experimental traumatic spinal cord injury. Journal of Stem Cell Research and Transplantation 1: 1008.
12. Carelli S., Giallongo T., Marfia G., Merli D., Ottobrini L., Degrassi A., Gorio A., (2015) Exogenous adult post mortem neural precursors attenuate secondary degeneration, and promote myelin sparing and functional recovery following experimental spinal cord injury. Cell Transplantation 24: 703–719.
13. Chen G., Shi J. X., Hang C. H., Xie W., Liu J., & Liu X., (2007) Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: A potential neuroprotective mechanism of recombinant human EPO (rhEPO). Neuroscience Letters 425(3): 177–182.
14. Corsini G. U., Pintus S., Chiueh C. C., Weiss J. F., Kopin I. J., (1985) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. European Journal of Pharmacology 119: 127–128.
15. Cui Y. F., Hargus G., Xu J. C., Schmid J. S., Shen Y. Q., Glatzel M., Bernreuther C., (2010) Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice. Brain 133: 189–204.
16. Del Zompo M., Ruiu S., Maggio R., Piccardi M. P., Corsini G. U., (1990) [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion binding sites in mouse brain: Pharmacological and biological characterization. Journal of Neurochemistry 54(6): 1905–1910.
17. Digicaylioglu M., Bichet S., Marti H. H., Wenger R. H., Rivas L. A., Bauer C., Gassmann M., (1995) Localization of specific EPO binding sites in defined areas of the mouse brain. Proceedings of the National Academy of Sciences of the United States of America 92: 3717–3720.
18. Doi D., Samata B., Katsukawa M., Kikuchi T., Morizane A., Ono Y., Takahashi J., (2014) Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2: 337–350.
19. Erbaş O., Çınar B. P., Solmaz V., Çavuşoğlu T., Ateş U., (2015) The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides 49: 1–5. doi: 10.1016/j.npep.2014.10.003.
20. Friling S., Andersson E., Thompson L. H., Jönsson M. E., Hebsgaard J. B., Nanou E., Ericson J., (2009) Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 106: 7613–7618.
21. Gao H. M., Liu B., Zhang W., Hong J. S., (2003) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson’ disease. Official Publication of the Federation of American Societies for Experimental Biology Journal 13: 1957–1959.
22. Gorio A., Gokmen N., Erbayraktar S., Yilmaz O., Madaschi L., Cichetti C., Brines M., (2002) Recombinant human EPO counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proceedings of the National Academy of Sciences of the United States of America 99: 9450–9455.
23. Hallett P. J., Cooper O., Sadi D., Robertson H., Mendez I., & Isacson O., (2014) Long-term health of dopaminergic neuron transplants in Parkinson’s disease patients. Cell Reports 7: 1755–1761.
24. Hallett P. J., Deleidi M., Astradsson A., Smith G. A., Cooper O., Osborn T. M., Isacson O., (2015) Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 16: 269–274.
25. Hantraye P., Brownell A. L., Elmaleh D., Spealman R. D., Wüllner U., Brownell G. L., Isacson O., (1992) Dopamine fiber detection by [11C]-CFT and PET in a primate model of Parkinsonism. Neuroreport 3: 265–268.
26. Haque N. S., LeBlanc C. J., Isacson O., (1997) Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplantation 6: 239–248.
27. Jelkmann W., (2011) Regulation of EPO production. The Journal of Physiology 589: 1251–1258.
28. Jensen E. C., (2013) Quantitative analysis of histological staining and fluorescence using image. Journal of Anatomical Record 296: 378–381.
29. Jia Y., Mo S. J., Feng Q. Q., Zhan M. L., Ou Yang L. S., Chen J. C., Lei W. L., (2014) EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson’s disease. Journal of Molecular Neuroscience 53: 117–124.
30. Kefalopoulou Z., Politis M., Piccini P., Mencacci N., Bhatia K., Jahanshahi M., Foltynie T., (2014) Long-term clinical outcome of fetal cell transplantation for Parkinson disease: Two case reports. Journal of the American Medical Association Neurology 71: 83–87.
31. Kim J. H., Auerbach J. M., Rodríguez-Gómez J. A., Velasco I., Gavin D., Lumelsky N., McKay R., (2002) Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature 4: 50–56.
32. Kim S. T., Son H. J., Choi J. H., Ji I. J., Hwang O., (2010) Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson’s disease. Brain Research 1306: 176–183.
33. Konishi Y., Chui D. H., Hirose H., Kunishita T., Tabira T., (1993) Trophic effect of EPO and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Research 609: 29–35.
34. Kriks S., Shim J. W., Piao J., Ganat Y. M., Wakeman D. R., Xie Z., Studer L., (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480: 547–551.
35. Liang C. L., Nelson O., Yazdani U., Pasbakhsh P., German D. C., (2004) Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: Human midbrain dopamine neurons. The Journal of Comparative Neurology 473: 97–106.
36. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Björklund A., (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 247: 574–577.
37. Marfia G., Madaschi L., Marra F., Menarini M., Bottai D., Formenti A., Gorio A., (2011) Adult neural precursors isolated from post mortem brain yield mostly neurons: An EPO-dependent process. Neurobiology of Disease 43: 86–98.
38. Marti H. H., (2004) EPO and the hypoxic brain. The Journal of Experimental Biology 207: 3233–3242.
39. Martínez-Cerdeño V., Noctor S. C., Espinosa A., Ariza J., Parker P., Orasji S., Kriegstein A. R., (2010) Embryonic MGE precursor cells grafted into adult rat striatum integrate and ameliorate motor symptoms in 6-OHDA-lesionedrats. Cell Stem Cell 6: 238–250.
40. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38: 1285–1291.
41. Morse J. K., Wiegand S. J., Anderson K., You Y., Cai N., Carnahan J., Alderson R. F., (1993) Brain-derived neurotrophic factor (BDNF). Prevents the degeneration of medial septal cholinergic neurons following fimbria transection. The Journal of Neuroscience 13: 4146–4156.
42. Ortiz L. A., Dutreil M., Fattman C., Pandey A. C., Torres G., Go K., Phinney D. G., (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proceedings of the National Academy of Sciences of the United States of America 104: 11002–11007.
43. Paxinos G., Franklin K. B. J., (2001) The mouse brain in stereotaxic coordinates, 2nd ed. Hong Kong, China: Academic Press.
44. Petroske E., Meredith G. E., Callen S., Totterdell S., Lau Y. S., (2001) Mouse model of Parkinsonism: A comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106(3): 589–601.
45. Pollock K., Dahlenburg H., Nelson H., Fink K. D., Cary W., Hendrix K., Nolta J. A., (2016) Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington’s disease mouse models. Molecular Therapy 24(5): 965–977.
46. Schultzberg M., Dunnett S. B., Björklund A., Stenevi U., Hökfelt T., Dockray G. J., Goldstein M., (1984) Dopamine and cholecystokinin immunoreactive neurons in mesencephalic grafts reinnervating the neostriatum: Evidence for selective growth regulation. Neuroscience 12: 17–32.
47. Shingo T., Sorokan S. T., Shimazaki T., Weiss S., (2000) EPO regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. The Journal of Neuroscience 21: 9733–9743.
48. Sofroniew M. V., (2005) Reactive astrocytes in neural repair and protection. Neuroscientist 11: 400–407.
49. Sundberg M., Bogetofte H., Lawson T., Jansson J., Smith G., Astradsson A., Isacson O., (2013) Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31: 1548–1562.
50. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S., (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872.
51. Thomas Tayra J., Kameda M., Yasuhara T., Agari T., Kadota T., Wang F., Date I., (2013) The neuroprotective and neurorescue effects of carbamylated EPO Fc fusion protein (CEPO-Fc) in a rat model of Parkinson’s disease. Brain Research 1502: 55–70.
52. Tillerson J. L., Miller G. W., (2003) Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of Parkinsonism. Journal of Neuroscience Methods 123: 189–200.
53. Tsui A., Isacson O., (2001) Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson’s disease. Journal of Neurology 258: 1393–1405.
54. Vaglini F., Pardini C., Viaggi C., Bartoli C., Dinucci D., & Corsini G. U., (2004) Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson’s disease. Journal of Neurochemistry 91: 285–298.
55. Viaggi C., Vaglini F., Pardini C., Caramelli A., Corsini G. U., (2009) MPTP-induced model of Parkinson’s disease in cytochrome P450 2E1 knockout mice. Neuropharmacology 56(8): 1075–1081.
56. Wernig M., Zhao J. P., Pruszak J., Hedlund E., Fu D., Soldner F., Jaenisch R., (2008) Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s disease. Proceedings of the National Academy of Sciences 105: 5856–5861.
57. Yang D., Zhang Z. J., Oldenburg M., Ayala M., Zhang S. C., (2008) Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 26: 55–63.
58. Yu J., Vodyanik M. A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J. L., Tian S., Thomson J. A., (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.
59. Wirdefeldt K., Adami H. O., Cole P., Trichopoulos D., Mandel J., (2011) Epidemiology and etiology of Parkinson’s disease: A review of the evidence. European Journal of Epidemiology 26(Suppl 1): S1–S58.
60. Zuddas A., Vaglini F., Fornai F., Corsini G. U., (1990) Embryonic neural grafts induce recovery in mice with permanent striatal lesion. Pharmacological Research 1: 3–4.